Regeneron Pharmaceuticals, Inc.
Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
Last updated:
Abstract:
The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
Status:
Grant
Type:
Utility
Filling date:
3 Nov 2016
Issue date:
6 Apr 2021